Primary prophylaxis in children with haemophilia

Blood Transfusion

Volumn 6, Issue SUPPL. 2, 2008, Pages

  Coppola, Antonio ^a   Di Capua, Mirko ^a   De Simone, Ciro ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bleeding; Children; Haemophilia; Prophylaxis; Treatment

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ARTHROPATHY; CLINICAL PRACTICE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HEALTH CARE SYSTEM; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; LOW DRUG DOSE; MORBIDITY; OUTCOME ASSESSMENT; PROPHYLAXIS; QUALITY OF LIFE; SUBSTITUTION THERAPY;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FACTOR IX; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; YOUNG ADULT;

EID: 56649103608     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0030-08     Document Type: Conference Paper

References (39)

1. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
2. Berntorp E, Boulyjenkov V, Brettler D, et al. Modern treatment of haemophilia. Bull World Health Organ 1995;73:691-701.
3. Ramgren O. Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Med Scand 1962; 171: 237-42.
4. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; issue (Suppl 77): 3-132.
5. Aledort L, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
6. Berntorp E, Astermark J, Bjorkman S, et al. Consensus perspectives on prophylaxis therapy for haemophilia: summary statement. Haemophilia 2003; 9 (Suppl 1): 1-4.
7. Ljung R. Prevention of bleeding in haemophilia: trends, overcoming barriers and future treatment options. Haemophilia 2007; 13 (Suppl 2): 1-3.
8. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 3 (Suppl 2):3-6.
9. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980;149:153-9.
10. Kreuz W, Escuriola-Ettingshausen C, Funk M, et al. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998; 4:413-7.
11. van den Berg HM, Fischer K, Mauser-Bunschoten EP, et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
12. Panicker J, Warrier I, Lusher J. The impact of prophylaxis on children with severe haemophilia. Journal : issue; pages
13. Yee TT, Beeton K, Griffioen A, et al. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002;8:76-82.
14. Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105:1109-13.
15. Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe haemophilia. Blood 2002; 99:2337-41.
16. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2006;2:CD003429.
17. Aronstam A, Arblaster PG, Rainsford SG, et al. Prophylaxis in haemophilia: a double-blind controlled trial. Br J Haematol 1976; 33:81-90.
18. Aronstam A, Kirk PJ, McHardy, et al. Twice weekly prophylactic therapy in haemophilia A. J Clin Pathol 1977; 30:65-7.
19. Carlsson M, Berntorp E, Bjorkman S, et al. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3:96-101.
20. Morfini M, Mannucci PM, Mariani G, et al. Evaluation of prophylactic replacement in haemophilia B. Scand J Haematol 1976; 16:41-7.
21. Mannucci PM. Need for randomized trials in haemophilia. J Thromb Haemost 2006; 4:501-2.
22. Aledort L, Ljung R, Blanchette V. Are randomized clinical trials the only truth? Not always. J Thromb Haemost 2006; 4:503-1.
23. The Medical and Scientific Advisory Council of the National Haemophilia Foundation. More on: are randomized clinical trials the only truth? Not always. J Thromb Haemost 2006; 4:1167-8.
24. Fischer K, Grobbee DE, van den Berg HM. RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia. Haemophilia 2007; 13:345-50.
25. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357:535-44.
26. Kilcoyne RF, Nuss R. Radiological assessment of haemophilic arthropathy with emphasis on MRI findings. Haemophilia 2003; 9 (Suppl 1):57-64.
27. Doria AS, Lundin B, Kilcoyne RF, et al. Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: expert MRI Working Group of the International Prophylaxis Study Group. Haemophilia 2005; 11:245-53.
28. Gringeri A. Prospective controlled study on prophylaxis: an Italian approach. Haemophilia 2003; 9 (Suppl 1): 38-43.
29. Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 2007; 13 (Suppl 2): 16-22.
30. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001; 7: 99-102.
31. Feldman BN, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
32. Spira J, Plyushch OP, Andreeva TA, Andreev Y. Prolonged bleeding-free period following prophylactic infusion of recombinant FVIII reconstituted with pegylated liposomes. Blood 2006; 108: 3668-73.
33. Fischer K, Astermark J, van der Bom JG, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8:753-60.
34. van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophiha. Haemophilia 2003; 9 (Suppl 1): 27-31.
35. Bohn RL, Schramm W, Bullinger M, et al. Outcome measures in haemophiha: more than just factor levels. Haemophilia 2004; 10 (Suppl 1): 2-8.
36. Remor E, Young NL, von Mackensen S, Lopatina EG. Disease-specific quality of life measurements tools for haemophilia patients. Haemophilia 2004; 10: 34-41.
37. Santagostino E, Mancuso ME, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-7.
38. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
39. Santagostino E, Mannucci PM, for the Italian Association of Hemophilia Centers (AICE). Guidelines for replacement treatment of haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000;6:1-10.